Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Insights into the Disease Mechanism of Vasculitis. Potential Target for Specific Therapy

16.05.2007
A potential therapeutic target for autoimmune vasculitis has been identified by researchers of the Franz Volhard Clinic for Cardiovascular Diseases (FVK) of the Charité – University Medicine Berlin/HELIOS-Klinikum and the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch.

They discovered that a specific surface receptor (NB1) mediates the expression of a molecule (autoantigen) on the surface of certain white blood cells, where the immune system recognizes and binds it. This reaction starts the inflammation process. Thus, NB1 is a potential drug target for ANCA-associated vasculitis, as Dr. Sibylle von Vietinghoff (FVK), Professor Friedrich Luft (FVK, MDC) and Professor Ralph Kettritz (FVK) report in the American journal Blood (Vol. 109, No. 10, pp. 4487-4493, May 15, 2007)*.

Autoimmune vasculitis is a broad term encompassing a group of disorders characterized by blood vessel inflammation. It is triggered by antibodies formed by the immune system which are no longer able to distinguish between “self” and “non-self”. The antibodies target the most common white blood cells, the neutrophil granulocytes, or more precisely an enzyme that is normally found in the cell plasma of these blood cells, proteinase 3 (PR3).

Neutrophil granulocytes are part of the immune system, and their primary function is to attack viruses and bacteria. In the cell plasma of all neutrophil granulocytes, the enzyme proteinase 3 (PR3) is present. PR3 plays a role in one form of vasculitis because it elicits the formation of autoantibodies. These antibodies are therefore called ANCA (antineutrophil cytoplasmatic autoantibodies).

However, ANCA autoantibodies only attack the white blood cells which “display” the enzyme PR3 on their surface. The blood cells which retain the enzyme inside the cell away from the cell surface avoid the attack of the autoantibodies. The binding of the ANCA antibodies to the PR3 localized on the cell membrane activates the white blood cells, which thereupon attack the body’s own structures and trigger the inflammation processes in the blood vessels. The resulting inflammation can affect any and all organs and become life-threatening.

Receptor protein

Prior to this study it was not known how the enzyme is presented on the membrane surface of the blood cells. Dr. von Vietinghoff and her colleagues in Berlin-Buch were able to show that it has a “helper” presenting it on the surface of the blood cells: the membrane anchor protein NB1 (CD177). For their study they tested and compared blood samples obtained from 200 healthy volunteer donors and patients with ANCA vasculitis. The researchers discovered that the enzyme PR3 and the receptor NB1 were more often found on the surfaces of blood cells in patients with ANCA vasculitis. Using molecular techniques the researchers were able to prove that NB1 is necessary for PR3 membrane presentation.

Aim – Development of a specific therapy

NB1 therefore appears to be a promising therapeutic target, according to Sibylle von Vietinghoff, Ralph Kettritz and Friedrich Luft. Although today there are treatments for vasculitis and related disorders such as Wegener’s granulomatosis, a rare but serious disease which affects all body organs including the kidneys, currently used drugs suppress the entire immune system. The disadvantage is that this makes patients more vulnerable to infection.

With unspecific immune therapy and dialysis, the kidneys of the affected patients often recover their function. “It is one of the few kidney diseases in which patients are able to come off dialysis,” Ralph Kettritz said. But a risk of recurrence always remains. If NB1 could be inhibited and PR3 expression on the blood cell surfaces prevented, vasculitis could be better controlled or even cured and recurrences avoided. “That is why our findings provide hope for patients with vasculitis,” he said. “A specific therapy approach based on our study may hold the key to overcoming the disease.”

Barbara Bachtler | alfa
Further information:
http://bloodjournal.hematologylibrary.org/

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>